Author: Rebecca Shover

Treatment with fitusiran prophylaxis led to a lower rate of bleeding events and an improved health-related quality of life in patients with hemophilia A or B with inhibitors. The observed safety profile of fitusiran in phase 3...

JAK2V617F variant allele frequency (VAF) >50% is associated with an increased risk of venous thrombosis in patients with polycythaemia vera (PV). This independent predictor distinguished between patients who were classified...

Significant disparities in health outcomes were observed across race, ethnicity, and socioeconomic status (SES) in patients with acute lymphoblastic leukemia (ALL). Differences in leukemia biology or disease prognosticators do...

The combination therapy of eprenetapopt plus azacytidine showed favorable efficacy and safety in patients with TP53-mutant myelodysplastic syndrome (MDS) and oligoblastic acute myeloid leukemia (AML). Patients with biallelic...

Liposomal daunorubicin/cytarabine (CPX-351) therapy did not result in different overall survival (OS) outcomes or response rates than venetoclax plus HMA therapy in patients with acute myeloid leukemia (AML) between 60 and 75...

The combination regimen of low-dose tacrolimus plus high-dose dexamethasone provides benefits over high-dose dexamethasone monotherapy in patients with immune thrombocytopenia (ITP). Both the initial response rates and the...

Talquetamab plus daratumumab demonstrated durable and deep responses in heavily pre-treated patients with refractory multiple myeloma (MM). Furthermore, the combination regimen was tolerable and did not show overlapping...